AbbVie remains strong long-term performer, offering a solid dividend yield and robust revenue growth despite share price dips ...

AbbVie (NYSE:ABBV) is scheduled to announce Q2 earnings results on Thursday, July 25th, before market open. Analysts are expecting a profit of $2.66 (-8.6% Y/Y) on revenue of $14.03B (+1.2% Y/Y ...

A bbVie (ABBV) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook gives a ...

AbbVie ABBV will report second-quarter 2022 results on Jul 29, before market open. In the last reported quarter, the company delivered an earnings surprise of 0.32%.

AbbVie will report Q2 earnings on Thursday. Investors watch for Humira impact and signs of recovery under new CEO.

AbbVie Inc. reported Q2 adjusted EPS of $2.65, beating the $2.57 consensus, with net revenues at $14.46 billion. Immunology sales rose to $6.97 billion, while Humira declined 29.8%. Oncology and ...

AbbVie (ABBV) came out with quarterly earnings of $3.37 per share, beating the Zacks Consensus Estimate of $3.31 per share. This compares to earnings of $3.11 per share a year ago. These figures ...

AbbVie expects full-year earnings in the range of $10.71 to $10.91 per share. AbbVie shares have climbed 14% since the beginning of the year, while the S&P's 500 index has risen 14%.

AbbVie's Q3 earnings will be announced on October 27th. Read why I consider ABBV stock as a de-risked investment opportunity with a generous dividend yield.

AbbVie (NYSE: ABBV) just reported results for the second quarter of 2024. AbbVie reported earnings per share of $2.65. This was above the analyst estimate for EPS of $2.57.